Last reviewed · How we verify
Depressin (PROPIZEPINE)
Depressin (generic name: PROPIZEPINE) is a propizepine drug. It is currently in Phase 2 development.
Depressin is thought to work by interacting with a specific target in the brain, although its exact mechanism is unknown.
Depressin (PROPIZEPINE) is a small molecule drug in the propizepine class, but its target and mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. There is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Depressin is not listed as an approved indication, and its commercial status is unclear. Further research is needed to understand its clinical use and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PROPIZEPINE |
|---|---|
| Drug class | propizepine |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is a complex computer, and Depressin is a software update that tries to fix a specific problem. However, since its target and mechanism are unknown, it's like trying to fix a problem without knowing what's causing it. More research is needed to understand how it works and what it does.
Approved indications
Common side effects
Key clinical trials
- Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) (Phase 1)
- NCT01626703 (NA)
- Safety and Performance of the SpineVision Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease in Skeletally Mature Patients - HEXANIUM ACIF Study (N/A)
- Safety and Performance of the Hexanium TLIF System in the Treatment of Skeletally Mature Patients Suffering From Degenerative Disc Disease - Hexanium TLIF Study (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Depressin CI brief — competitive landscape report
- Depressin updates RSS · CI watch RSS
Frequently asked questions about Depressin
What is Depressin?
How does Depressin work?
What is the generic name of Depressin?
What drug class is Depressin in?
What development phase is Depressin in?
Related
- Drug class: All propizepine drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing